Abstract
Background
Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects older adults, and tafamidis has proven efficacy in reducing mortality and hospitalizations in this population. However, its clinical benefit in octogenarians remains uncertain due to limited life expectancy, frailty, and other age-related factors. This meta-analysis evaluates the effect of tafamidis in patients aged ≥ 80 years, aiming to address the gap in evidence regarding the therapy’s impact in this population.
Methods
A systematic review and meta-analysis were conducted by searching PubMed, Embase, and Cochrane databases for studies comparing tafamidis versus control in patients aged ≥ 80 years with transthyretin amyloidosis. The primary outcome was all-cause mortality. Hazard ratios (HRs) were pooled using a random-effects model, and heterogeneity was assessed using I² statistics.